Incidence of dermatologic adverse events in patients with cancer treated with concurrent immune checkpoint inhibitors and radiation therapy: A systematic review and meta-analysis.
作者信息
Yan Bernice Y, Wasilewski Gloria, Lacouture Mario E, Barker Christopher A
机构信息
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York.
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
出版信息
J Am Acad Dermatol. 2021 Mar;84(3):871-875. doi: 10.1016/j.jaad.2020.10.071. Epub 2020 Oct 31.
Abstract
摘要
相似文献
1
Incidence of dermatologic adverse events in patients with cancer treated with concurrent immune checkpoint inhibitors and radiation therapy: A systematic review and meta-analysis.接受免疫检查点抑制剂与放射治疗联合治疗的癌症患者皮肤不良事件的发生率：一项系统评价和荟萃分析。
J Am Acad Dermatol. 2021 Mar;84(3):871-875. doi: 10.1016/j.jaad.2020.10.071. Epub 2020 Oct 31.
2
Immune checkpoint inhibitor-related dermatologic adverse events.免疫检查点抑制剂相关的皮肤不良反应。
J Am Acad Dermatol. 2020 Nov;83(5):1255-1268. doi: 10.1016/j.jaad.2020.03.132. Epub 2020 May 23.
3
Immune Profiling of Dermatologic Adverse Events from Checkpoint Blockade Using Tissue Cyclic Immunofluorescence: A Pilot Study.利用组织循环免疫荧光对检查点阻断引起的皮肤不良事件进行免疫谱分析：一项试点研究。
J Invest Dermatol. 2024 Aug;144(8):1887-1890.e5. doi: 10.1016/j.jid.2024.01.024. Epub 2024 Feb 14.
4
Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy.免疫检查点抑制剂治疗肺癌患者的皮肤毒性。
Clin Lung Cancer. 2021 May;22(3):195-200.e1. doi: 10.1016/j.cllc.2021.01.006. Epub 2021 Jan 22.
5
Cutaneous adverse events to immune checkpoint inhibitors in pediatric populations: A retrospective cohort study.儿科人群中免疫检查点抑制剂的皮肤不良事件：一项回顾性队列研究。
J Am Acad Dermatol. 2021 Dec;85(6):1587-1589. doi: 10.1016/j.jaad.2020.11.033. Epub 2020 Nov 27.
6
Cutaneous adverse reactions to anti-PD-1 treatment-A systematic review.抗 PD-1 治疗的皮肤不良反应——系统评价。
J Am Acad Dermatol. 2020 Nov;83(5):1415-1424. doi: 10.1016/j.jaad.2020.04.058. Epub 2020 Apr 19.
7
Cancer Therapy-induced Dermatotoxicity as a Window to Understanding Skin Immunity.癌症治疗相关皮肤毒性：揭示皮肤免疫的窗口
Hematol Oncol Clin North Am. 2024 Oct;38(5):1011-1025. doi: 10.1016/j.hoc.2024.05.002. Epub 2024 Jun 12.
8
Radiation pneumonitis in patients with non-small-cell lung cancer receiving chemoradiotherapy and an immune checkpoint inhibitor: a retrospective study.接受放化疗及免疫检查点抑制剂治疗的非小细胞肺癌患者放射性肺炎：一项回顾性研究
Radiat Oncol. 2021 Dec 4;16(1):231. doi: 10.1186/s13014-021-01930-2.
9
Methotrexate in the treatment of immune checkpoint blocker-induced bullous pemphigoid.甲氨蝶呤治疗免疫检查点抑制剂诱导的大疱性类天疱疮。
Eur J Cancer. 2021 Dec;159:34-37. doi: 10.1016/j.ejca.2021.09.032. Epub 2021 Oct 30.
10
Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.计划靶区作为不可切除 III 期非小细胞肺癌患者接受放化疗联合及/或序贯免疫检查点抑制治疗后疾病进展的预测因素。
Invest New Drugs. 2022 Feb;40(1):163-171. doi: 10.1007/s10637-021-01143-0. Epub 2021 Aug 5.
引用本文的文献
1
Chinese clinical practice guidelines for the prevention and treatment of radiation-induced dermatitis.放射性皮炎防治中国临床实践指南
Precis Radiat Oncol. 2023 Sep 10;7(3):160-172. doi: 10.1002/pro6.1208. eCollection 2023 Sep.
2
Radiation Dermatitis: Radiation-Induced Effects on the Structural and Immunological Barrier Function of the Epidermis.放射性皮炎：辐射对表皮结构和免疫屏障功能的诱导效应。
Int J Mol Sci. 2024 Mar 15;25(6):3320. doi: 10.3390/ijms25063320.
3
Risk of Adverse Events in Cancer Patients Receiving Nivolumab With Ipilimumab: A Meta-Analysis.接受纳武利尤单抗联合伊匹木单抗治疗的癌症患者发生不良事件的风险：一项荟萃分析。
Front Oncol. 2022 Jun 23;12:877434. doi: 10.3389/fonc.2022.877434. eCollection 2022.
本文引用的文献
1
Immune checkpoint inhibitor-related dermatologic adverse events.免疫检查点抑制剂相关的皮肤不良反应。
J Am Acad Dermatol. 2020 Nov;83(5):1255-1268. doi: 10.1016/j.jaad.2020.03.132. Epub 2020 May 23.
2
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor.针对程序性死亡受体-1（PD-1）受体的药物所致皮肤不良事件的特征与管理
Eur J Cancer. 2016 Jun;60:12-25. doi: 10.1016/j.ejca.2016.02.010. Epub 2016 Apr 1.
3
Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis.靶向癌症治疗患者的瘙痒：系统评价和荟萃分析。
J Am Acad Dermatol. 2013 Nov;69(5):708-720. doi: 10.1016/j.jaad.2013.06.038. Epub 2013 Aug 24.
4
Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic.283 例癌症患者皮肤病不良反应对生活质量的影响：皮肤科转诊诊所的问卷调查研究。
Am J Clin Dermatol. 2013 Aug;14(4):327-33. doi: 10.1007/s40257-013-0021-0.
5
The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis.癌症患者使用伊匹单抗相关皮疹风险的系统评价和荟萃分析。
J Am Acad Dermatol. 2013 Sep;69(3):e121-8. doi: 10.1016/j.jaad.2012.12.963. Epub 2013 Jan 26.
Zotero 插件